Clinical Cooperation Unit Pediatric Oncology
Prof. Dr. med. Olaf Witt
Non-effective (left) and effective drug treatment (right) of three-dimensional microtumors. The microtumors were stained with three fluorescent dyes labelling all cells (blue), viable cells (red), and dying cells (green).
© dkfz.de
Welcome to the homepage of the Clinical Cooperation Unit Pediatric Oncology, where we are dedicated to advancing pediatric cancer research through the translation of preclinical findings into clinical trials.
Our team of expert researchers is aiming to develop preclinical models, investigating mechanisms of action, conducting drug screens, and clinical trials with new innovative treatments to translate promising treatments to children with cancer. Our team is constantly working to identify new biomarkers that enable to predict treatment response and inform clinical trial design. As such, the department is an essential part of the "Translational Pediatric Oncology" program of the Hopp Children’s Cancer Center Heidelberg (KiTZ) and is closely collaborating with groups from the preclinical and clinical programs of the KiTZ.
Our preclinical activities are centered around developing robust in vitro and in vivo disease models and generate science-driven preclinical data packages to initiate and guide clinical trial development with innovative treatments.
Our KiTZ Clinical Trial Unit has a strong expertise in pediatric phase I-III trial development and coordination of international clinical trials. We work closely with international partners in academia, industry, and the healthcare sector to design and conduct clinical trials that offer the most promising treatments to children with cancer and improve clinical practice in a sustained manner. Our commitment to international collaboration ensures that our clinical trials have the greatest possible impact.
Thank you for visiting our website, and please do not hesitate to contact us if you have any questions or would like to learn more about our work.
